MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company ...
PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...
Equities researchers at Piper Sandler assumed coverage on shares of Merus (NASDAQ:MRUS – Get Free Report) in a report issued ...
News Medical on MSN3d
Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AIInsilico Medicine ( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today ...
Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics and headquartered in Switzerland, ...
Royal Bank of Canada reissued their outperform rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They ...
Yelena Korochkina, winner of the 2024 Presidential Prize in Science and Innovation for Young Scientists The prize was awarded for developing innovative methods for the effective implementation of ...
NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company with a market capitalization of $32.36 million, has initiated a Phase 2 clinical trial for RLYB212, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback